

Klinik laborator diagnostikada innovatsion texnologiyalardan foydalanish, muammolar va yechimlar, 2023



**KLINIK LABORATOR  
DIAGNOSTIKADA INNOVATSION  
TEXNOLOGIYALARDAN  
FOYDALANISH, MUAMMOLAR VA  
YECHIMLAR**  
**xalqaro ilmiy-amaliy  
anjuman**  
**18 aprel 2023 yil**



**O'zbekiston Respublikasi Sog'liqni saqlash vazirligi**

**WWW.SSV.UZ**

**Toshkent tibbiyot akademiyasi [www.tma.uz](http://www.tma.uz)**

diseases .....	230
<b>Berger I.V.</b> Цитокиновые сдвиги у гематологических пациентов с тромбозами .....	232
<b>Bobojonova Sh.D., Saidov A.B., Samatova L.D.</b> Donorlarda brutsel-lyoz diagnostikasi .....	234
<b>Djurabayeva M.H, Muxiddinova M.</b> Comparative characteristics of lung tuberculosis treatment models .....	235
<b>Do'stmuhammedova R.Z., Xasanova M.A., Xudayberganova A.A.</b> Some aspects of hair research in the forensic relationship .....	237
<b>Do'stmuhammedova R.Z., Xasanova M.A., Xudayberganova A.A.</b> Sud tibbiy munosabatlarda sochlarni tekshirishning aspektlari .....	238
<b>Elboyeva H.D.</b> Kaltsiyning klinik ahamiyati .....	239
<b>Ergashev A.D., Maxamatjanova N.M.</b> Correction of post-Covid-19 anxiety-phobic disorders by erickson hypnosis .....	240
<b>Ergasheva U.A.</b> Alaninaminotransferaza klinik ahamiyati .....	241
<b>Fayzullayev Sh.Sh., Saidov A.B., Kurbonova Z.Ch.</b> Qon tarkibiy qismlari infeksiyon xavfsizligini ta'minlash usullari .....	243
<b>Gafurova S.Sh., Yusuphadjayeva S.T.</b> Ta'sirlangan ichak sindromida xavotir-fobik buzilishlar, ularda psixoterapiya va psixofarmakoterapiyaning samaradorligi .....	245
<b>Hamrayev B.O'.</b> O'tkir nurlanish ta'sirida laboratoriya hayvonlarining o'pkasida morfologik o'zgarishlarning o'ziga xosligi .....	246
<b>Islamova Z.S., Babadjanova Sh.A., Musaeva N.B.</b> Gemorragik vaskulitda endotelial disfunksiya rivojlanishida villebrand omilining ahamiyati .....	248
<b>Islamova Z.S., Musaeva N.B., Yusupxodjaeva X.S., Botirxujaeva A.A.</b> Immun mikrotrombovaskulitda trombomodulin omilining ahamiyati .....	249
<b>Jienbaeva A.A., Kurbonova Z.Ch.</b> Diagnosis of kidney damage in heart failure .....	251
<b>Jiyenbayeva A.A., Kurbonova Z.Ch.</b> Yurak yetishmovchiligida buyrak shikastlanishining diagnostikasi .....	252
<b>Jumanazarov S.B., Jabbarov O.O.</b> Surunkali glomerulonefrit rivojlanishida nomzod genlarning roli .....	254
<b>Jumayeva Z.S.</b> Albumin va uni laborator tahlil qilish .....	256
<b>Jumayeva Z.S.</b> Bilirubin fraksiyalarini laborator tahlil qilish .....	257

ko'rsatgichlarini laboratoriyaviy nazorati. // Digitalization is the future of medicine. – 2021. – B. 393-395.

## **DIAGNOSIS OF KIDNEY DAMAGE IN HEART FAILURE**

**Jienbaeva A.A., Kurbonova Z.Ch.**

**Tashkent medical academy**

Cardiovascular diseases (CVD) are the leading cause of death worldwide, from which an estimated 17.9 million people die every year. Together with diseases of the cardiovascular system, one of the most frequent manifestations is kidney pathology. Diagnostics remains one of the main tasks of doctors.

To assess the functional state of the kidneys in adults today, mainly 2 formulas are used: MDRD (Modification of Diet in Renal Disease) and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), which allow you to determine the glomerular filtration rate, as well as the Cockcroft-Gault formula for calculating creatinine clearance. A recent study compared the above formulas in patients with chronic heart failure (CHF) with an isotopic method for determining the glomerular filtration rate (GFR).

The best results for comparability with the data of the reference method were shown by the formula CKD-EPI. Thus, for the diagnosis of chronic kidney disease (CKD) and its stages, it is advisable to use the CKD-EPI formula, at the same time it is impossible to abandon the Cockcroft-Gault formula, since in clinical trials of drugs, kidney function was usually assessed by creatinine clearance calculated using the Cockcroft-Gault formula. In this regard, the dose of the drug should be adjusted according to the official instructions, and if it refers to creatinine clearance, then the Cockcroft-Gault formula should be used. These seemingly "little things" should not be neglected, because the difference between the GFR calculated according to the formulas MDRD or CKD-EPI and creatinine clearance according to the Cockcroft-Gault formula can reach 20%. Approximately one third of patients with CHF have renal dysfunction.

At the same time, it is necessary to carefully interpret the decrease (GFR) in patients with exacerbation of CHF as a manifestation of chronic kidney disease, since one third of patients with acute decompensation of CHF develop acute kidney damage. It is not easy to distinguish between acute kidney injury (AKI) and CKD during hospitalization of a patient with acute decompensation of CHF. Diagnosis of AKI is based on an assessment of the dynamics of serum creatinine and diuresis and does not allow to diagnose AKI at the time of hospitalization. The use of AKI biomarkers, among which the most studied are lipocalin associated with neutrophil gelatinase (NGAL), interleukin 18 (IL-18), acute kidney injury molecule – 1 (KIM-1), is still difficult to apply in practical work due to the lack of generally accepted quantitative criteria of norm. Of course, We would like to have a reliable biomarker of AKI (like troponin in acute coronary syndrome), which would allow early diagnosis of AKI.

Our experience with the use of biomarkers indicates that they are more suitable for the diagnosis of AKI associated with pronounced structural changes in the kidneys, for example, with exogenous poisoning, drug effects. If AKI is caused mainly by hemodynamic disorders (acute cardiorenal syndrome), then the role of biomarkers is less obvious. In this regard, the possibility of using a laboratory panel of several biomarkers characterizing different levels of kidney damage is discussed. Theoretically, this approach is justified, but does it provide additional clinical benefits, not to mention the economic component? Modern cardiology has already passed this stage (the joint use of myoglobin and troponin), today troponin is used as a biomarker of myocardial necrosis. For acute heart failure or acute decompensation of CHF already at the stage of hospitalization, it is important to distinguish what takes place: CKD or AKI, which is not easy to do, since most AKI develops against the background of previous CKD. On the one hand, CKD predisposes to the development of AKI, on the other, AKI aggravates and accelerates the progression of CKD.

#### **References.**

1. Курбонова З.Ч., Бабаджанова Ш.А. Цитологик ташхисга кириш: ўқув қўлланма. Тошкент, 2022. 137 б.
2. Курбонова З.Ч., Бабаджанова Ш.А. Цитологик ташхисга кириш: электрон ўқув қўлланма. 2022, 146 б.
3. Курбонова З.Ч., Бабаджанова Ш.А. Лаборатория иши: ўқув қўлланма. 2023, 150 б.
4. Babadjanova Sh.A., Kurbonova Z.Ch. Qon kasalliklari: o'quv qo'llanma. 2023, 156 b.
5. Kurbonova Z.Ch., Babadjanova Sh.A. Laboratoriya ishi: o'quv qo'llanma. Toshkent, 2022. 140 b.
6. Kurbonova Z.Ch., Babadjanova Sh.A. Laboratoriya ishi: elektron o'quv qo'llanma. Toshkent, 2022. 176 b.
7. Kurbonova Z.Ch., Babadjanova S.A. Sitologik tashxisga kirish: o'quv qo'llanma. Toshkent, "Hilol nashr", 2021. 152 b.
8. Kurbonova Z.Ch., Babadjanova Sh.A. Sitologik tashxis asoslari: o'quv – uslubiy qo'llanma. Toshkent, 2022. 47 b.
9. Kurbonova Z.Ch., Babadjanova Sh.A. Sitologik diagnostika asoslari: o'quv – uslubiy qo'llanma. Toshkent, 2022. 47 b.
10. Kurbonova Z.Ch., Babadjanova Sh.A., Saidov A.B. Gematologik kasalliklar sitologik diagnostikasi: o'quv uslubiy qo'llanma. Toshkent, 2021. – 56 b.
11. Kurbonova Z.Ch., Babadjanova Sh.A., Sayfutdinova Z.A. Laboratory work: o'quv qo'llanma. Toshkent, 2023.
12. Kurbonova Z.Ch., Babadjanova Sh.A., Sayfutdinova Z.A. Introduction to cytological diagnostics: o'quv qo'llanma. Toshkent, 2023.

## **YURAK ETISHMOVCHILIGIDA BUYRAK SHIKASTLANISHINING DIAGNOSTIKASI**

**Jiyenbayeva A.A., Kurbonova Z.Ch.  
Toshkent tibbiyot akademiyasi**